From: <u>Dave Brown</u>

To: Alyson Berliner; James Major

Cc:Robert VittiSubject:Re: ARVO abstract

Date: Wednesday, March 3, 2010 12:45:07 PM
Attachments: DA VINCI Late Breaker ARVO abstract.pdf

With the changes. Enjoy!

Let me know if you see anything else.

Dave

On 3/3/10 12:21 PM, "Alyson Berliner" < <u>Alyson.Berliner@regeneron.com</u> > wrote:

Thanks, Dave!!

Only two comments:

Results: Anatomical effects (mean change in CRT) for each VTE arm ranged from -127 $\mu$ m to -195 $\mu$ m and were significantly greater than the mean change in CRT for the laser arm (-68 $\mu$ m; p<0.01).

Conclusion: In this patient population at the 24-week primary endpoint, intravitreal VTE was generally well tolerated and produced significant improvements from baseline in visual acuity and retinal thickness, and a trend toward improvement in central retinal sensitivity as compared to laser photocoagulation.

(To date, we do not have p values for retinal sensitivity. ?I will see if we can calculate them. ?But for now, we should probably say there is a trend…)

Let me know if you have any questions.

Thanks! Alyson

Alyson J Berliner, MD,PhD
Director, Clinical Sciences, Ophthalmology
Regeneron Pharmaceuticals
(914) 785-3049 (office)
(914) 815-8875 (mobile)
(914) 593-1555 (fax)
Alyson.Berliner@regeneron.com

From: Dave Brown [mailto:dmbmd@houstonretina.com]

**Sent:** Wednesday, March 03, 2010 12:51 PM

To: Alyson Berliner; James Major



**Cc:** Robert Vitti

**Subject:** Re: ARVO abstract

Here is the submitted ARVO abstract-- Please proof to make sure I didn't miss anything. We are fine on length.

**DMB** 

On 3/2/10 7:09 PM, "Alyson Berliner" < Alyson.Berliner@regeneron.com > wrote:

Hi Dave,

Here is the updated abstract with your edits, the endophthalmitis info, and some other tweaks to reduce the character count. When you submit, I do not think you will need the "Background" section. You are welcome to add part of this section to another section or leave it out, as space dictates. Please let me know if you have any additional questions/comments, or if you need any assistance in the submission. Also, can you let me know when the abstract has been submitted successfully?

Thanks so much! Alyson

This e-mail and any attachment hereto, is intended only for use by the addressee(s) named above and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, any dissemination, distribution or copying of this email, or any attachment hereto, is strictly prohibited. If you receive this email in error please immediately notify me by return electronic mail and permanently delete this email and any attachment hereto, any copy of this e-mail and of any such attachment, and any printout thereof. Finally, please note that only authorized representatives of Regeneron Pharmaceuticals, Inc. have the power and authority to enter into business dealings with any third party.

This e-mail and any attachment hereto, is intended only for use by the addressee(s) named above and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, any dissemination, distribution or copying of this email, or any attachment hereto, is strictly prohibited. If you receive this email in error please immediately notify me by return electronic mail and permanently delete this email and any attachment hereto, any copy of this e-mail and of any such attachment, and any printout thereof. Finally, please note that only authorized representatives of Regeneron Pharmaceuticals, Inc. have the power and authority to enter into business dealings with any third party.

